文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

口服司美格鲁肽与2型糖尿病患者心力衰竭结局:SOUL随机临床试验的二次分析

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
PubMed 文献 · JAMA Intern Med · 2026-01-01
一句话结论在伴有心力衰竭病史的2型糖尿病患者中,口服司美格鲁肽较安慰剂降低复合心衰结局风险(HR 0.78,95%CI 0.63-0.96),且未增加严重不良事件。

SOUL试验的二次分析纳入9650例2型糖尿病合并动脉粥样硬化性心血管疾病和/或慢性肾脏病患者,按基线有无心力衰竭病史分层,随机接受每日一次口服司美格鲁肽或安慰剂。中位随访47.5个月,有HF病史者(2229例,23.1%)复合心衰结局的HR为0.78(95%CI 0.63-0.96),无HF病史者为1.01(95%CI 0.84-1.20),交互作用P=0.06。有HF病史者中,射血分数保留型HR为0.59(95%CI 0.39-0.86),射血分数降低型HR为0.98(95%CI 0.70-1.38)。有HF病史者严重不良事件发生率司美格鲁肽组53.8% vs 安慰剂组57.1%。作者认为这些数据支持口服司美格鲁肽在2型糖尿病合并心衰患者中降低心衰事件的潜在获益。

要点

  • 有HF病史的T2D患者中,口服司美格鲁肽较安慰剂降低复合心衰结局(心衰住院、紧急心衰就诊或心血管死亡)(HR 0.78,95%CI 0.63-0.96)。
  • 无HF病史者中,口服司美格鲁肽对复合心衰结局无显著影响(HR 1.01,95%CI 0.84-1.20),交互作用P=0.06。
  • 有HF病史者中,射血分数保留型心衰患者HR为0.59(95%CI 0.39-0.86),射血分数降低型HR为0.98(95%CI 0.70-1.38)。
  • 有HF病史者中,口服司美格鲁肽与安慰剂对MACE风险降低无异质性(有HF病史HR 0.83,95%CI 0.68-1.01;无HF病史HR 0.86,95%CI 0.75-0.98;交互作用P=0.77)。
  • 有HF病史者中,严重不良事件发生率司美格鲁肽组53.8% vs 安慰剂组57.1%,未增加严重不良事件风险。

适用人群与场景

  • 2型糖尿病合并动脉粥样硬化性心血管疾病和/或慢性肾脏病的患者,按基线有无心力衰竭病史分层。
  • SOUL试验在33个国家444个中心开展,纳入时间为2019年6月17日至2021年3月24日。
  • 有HF病史者2229例(23.1%),其中射血分数保留型991例(10.3%)、射血分数降低型592例(6.1%)、亚型未知646例(6.7%)。

处置流程与药物剂量

  • 口服司美格鲁肽每日一次或安慰剂,在标准治疗基础上给药。
  • 主要终点为预设复合心衰结局:首次发生心衰住院、紧急心衰就诊或心血管死亡的时间。

研究设计与关键结果

  • 二次分析纳入9650例患者,中位年龄66.0岁(IQR 61.0-72.0),女性2790例(28.9%),平均随访47.5个月(SD 10.9)。
  • 有HF病史者复合心衰结局:口服司美格鲁肽 vs 安慰剂 HR 0.78(95%CI 0.63-0.96);无HF病史者 HR 1.01(95%CI 0.84-1.20);交互作用P=0.06。
  • 有HF病史者中,射血分数保留型HR 0.59(95%CI 0.39-0.86),射血分数降低型HR 0.98(95%CI 0.70-1.38)。
  • MACE风险:有HF病史者HR 0.83(95%CI 0.68-1.01),无HF病史者HR 0.86(95%CI 0.75-0.98),交互作用P=0.77。
  • 有HF病史者严重不良事件:口服司美格鲁肽组594例(53.8%) vs 安慰剂组642例(57.1%)。

证据类型、等级与局限

  • 证据类型:3b期随机、双盲、安慰剂对照、事件驱动临床试验(SOUL)的二次分析。
  • 试验注册号:ClinicalTrials.gov NCT03914326。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于2型糖尿病合并动脉粥样硬化性心血管疾病和/或慢性肾脏病且有心力衰竭病史的患者,口服司美格鲁肽可能降低复合心衰结局风险(心衰住院、紧急心衰就诊或心血管死亡)。
  • 对于无心力衰竭病史的上述患者,口服司美格鲁肽对复合心衰结局的影响无显著差异(HR 1.01,95%CI 0.84-1.20)。
  • 有HF病史者中,射血分数保留型心衰患者可能从口服司美格鲁肽中获益(HR 0.59,95%CI 0.39-0.86),射血分数降低型心衰患者未观察到显著获益(HR 0.98,95%CI 0.70-1.38)。
  • 作者认为这些数据支持口服司美格鲁肽在2型糖尿病合并心衰患者中降低心衰事件的潜在获益。

指南或共识出处

  • SOUL随机临床试验(NCT03914326)的二次分析,发表于JAMA Internal Medicine。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Heart failure (HF) is a common complication of type 2 diabetes (T2D). Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people with T2D in the SOUL trial, but the impact on HF outcomes in these participants is unknown.

OBJECTIVE: To evaluate the effect of oral semaglutide on HF events, MACE, and safety among participants with or without HF at baseline.

DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, which was conducted at 444 centers in 33 countries. Participants were enrolled from June 17, 2019, to March 24, 2021, and had T2D and atherosclerotic CV disease and/or chronic kidney disease, stratified according to the presence or absence of HF history at baseline. Data were analyzed from December 2024 to August 2025.

INTERVENTION: Once-daily oral semaglutide or placebo in addition to standard of care.

MAIN OUTCOMES AND MEASURES: Prespecified composite HF outcome (time to first occurrence of HF hospitalization, urgent HF visit, or CV death).

RESULTS: Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 2790 [28.9%] female) were randomized, with a mean (SD) follow-up of 47.5 (10.9) months. Of these participants, 2229 (23.1%) had HF history (991 [10.3%] with preserved ejection fraction, 592 [6.1%] with reduced ejection fraction, and 646 [6.7%] with unknown subtype). For participants with HF at baseline, the hazard ratio (HR) for risk of the composite HF outcome with oral semaglutide vs placebo was 0.78 (95% CI, 0.63-0.96) and was 1.01 (95% CI, 0.84-1.20) in those without HF at baseline (P for interaction = .06). Among participants with HF, the HR was 0.59 (95% CI, 0.39-0.86) in those with preserved ejection fraction and 0.98 (95% CI, 0.70-1.38) in those with reduced ejection fraction. There was no heterogeneity in the risk reduction of MACE with oral semaglutide in participants with HF history (HR, 0.83; 95% CI, 0.68-1.01) or without HF history (HR, 0.86; 95% CI, 0.75-0.98) (P for interaction = .77). Serious adverse event occurrence among participants with HF was similar with oral semaglutide (594 [53.8%]) and placebo (642 [57.1%]).

CONCLUSIONS AND RELEVANCE: In this secondary analysis of the SOUL randomized clinical trial, among individuals with T2D, atherosclerotic CV disease, and/or chronic kidney disease, a reduction of HF events was observed with use of oral semaglutide compared with placebo in those with a history of HF, without increasing the risk of serious adverse events. These data support the potential benefit of oral semaglutide in reducing HF events in people with T2D and HF.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03914326.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Pop-Busui R, Rasmussen S, Deanfield JE, et al. Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA Intern Med. 2026. PMID: 41627802. doi:10.1001/jamainternmed.2025.7774

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。